ArticleJournal of radiation research2018
Strategies for prediction and mitigation of radiation-induced liver toxicity.
Article in Journal of radiation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Comparative outcomes of stereotactic body radiotherapy versus radiofrequency ablation in hepatocellular carcinoma within Milan criteria: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prevention of radiation-induced liver toxicity after interstitial HDR brachytherapy by pentoxifylline and ursodeoxycholic acid: patient compliance and outcome in a randomized trial.Journal of cancer research and clinical oncology · 2023Trial
- The identification of genes related to METTL14 inhibition in radiation-induced hepatocyte death based on bioinformatics analysis.Scientific reports · 2026Article
- Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.Frontiers in oncology · 2026Review
- Analysis of metabolic liver function and MR-morphological cholestatic parameters after SBRT of liver metastases.Radiation oncology (London, England) · 2025Article
- Evaluation of clinical and volumetric outcomes following adaptive gamma knife radiosurgery for brain metastases.Journal of neuro-oncology · 2025Article
- Review
- Linear Federated Learning for Outcome Prediction With Application to Hepatocellular Carcinoma Radiotherapy.JCO clinical cancer informatics · 2025Article
- Response‑adapted involved site radiation therapy for hepatic marginal zone B‑cell lymphoma: A case report.Oncology letters · 2025Article
- The emerging role of IL-17A across different types of radiation-induced normal tissue injuries.Therapeutic advances in medical oncology · 2025Review
- Understanding and using Animal Models of Hepatotoxicity.Current pharmaceutical design · 2025Review
- Review
- Diffeomorphic transformer-based abdomen MRI-CT deformable image registration.Medical physics · 2024Article
- Article
- Time variation of high-risk groups for liver function deteriorations within fluctuating long-term liver function after hepatic radiotherapy in patients with hepatocellular carcinoma.European journal of medical research · 2024Article
- Advances in gross tumor target volume determination in radiotherapy for patients with hepatocellular carcinoma.Frontiers in oncology · 2024Review
- Determination of hepatic extraction fraction with gadoxetate low-temporal resolution DCE-MRI-based deconvolution analysis: validation with ALBI score and Child-Pugh class.Journal of medical radiation sciences · 2023Article
- Radiation-induced liver disease: beyond DNA damage.Cell cycle (Georgetown, Tex.) · 2023Review
- Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment.ACS omega · 2023Article
- Microarray analysis identifies coding and non-coding RNA markers of liver injury in whole body irradiated mice.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although well described in the 1960s, liver toxicity secondary to radiation therapy, commonly known as radiation-induced liver disease (RILD), remains a major challenge. RILD encompasses two distinct clinical entities, a 'classic' form, composed of anicteric hepatomegaly, ascites and elevated alkaline phosphatase; and a 'non-classic' form, with liver transaminases elevated to more than five times the reference value, or worsening of liver metabolic function represented as an increase of 2 or more points in the Child-Pugh score classification. The risk of occurrence of RILD has historically limited the applicability of radiation for the treatment of liver malignancies. With the development of 3D conformal radiation therapy, which allowed for partial organ irradiation based on computed tomography treatment planning, there has been a resurgence of interest in the use of liver irradiation. Since then, a large body of evidence regarding the liver tolerance to conventionally fractionated radiation has been produced, but severe liver toxicities has continued to be reported. More recently, improvements in diagnostic imaging, radiation treatment planning technology and delivery systems have prompted the development of stereotactic body radiotherapy (SBRT), by which high doses of radiation can be delivered with high target accuracy and a steep dose gradient at the tumor - normal tissue interface, offering an opportunity of decreasing toxicity rates while improving tumor control. Here, we present an overview of the role SBRT has played in the management of liver tumors, addressing the challenges and opportunities to reduce the incidence of RILD, such as adaptive approaches and machine-learning-based predictive models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.